These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 2524997)
1. Antibacterial activity of trospectomycin (U-63366F) and initial evaluations of disk diffusion susceptibility tests. Barry AL; Jones RN; Thornsberry C Antimicrob Agents Chemother; 1989 Apr; 33(4):569-72. PubMed ID: 2524997 [TBL] [Abstract][Full Text] [Related]
3. Cefmetazole and trospectomycin in vitro susceptibility testing interpretive criteria and quality control guidelines for Neisseria gonorrheae. Jones RN; Erwin ME; Washington JA; Koontz FP; Murray PR; Gerlach EH Diagn Microbiol Infect Dis; 1992; 15(7):627-32. PubMed ID: 1424520 [TBL] [Abstract][Full Text] [Related]
4. In vitro antibacterial activity of trospectomycin (U-63,366F) against anaerobic bacteria and aerobic gram-positive cocci in Chile. Montiel F; Kaltwasser G; Pinto ME; Lam M Diagn Microbiol Infect Dis; 1991; 14(3):259-64. PubMed ID: 1832369 [TBL] [Abstract][Full Text] [Related]
5. Activity of trospectomycin against Bacteroides fragilis and other Bacteroides species. Jacobus NV; Tally FP Antimicrob Agents Chemother; 1988 Apr; 32(4):584-6. PubMed ID: 2967671 [TBL] [Abstract][Full Text] [Related]
6. In vitro activity against aerobes and anaerobes of trospectomycin versus spectinomycin. Gismondo MR; Chisari G; Lo Bue AM Drugs Exp Clin Res; 1991; 17(2):101-4. PubMed ID: 1830841 [TBL] [Abstract][Full Text] [Related]
7. In vitro activity of trospectomycin (U-63366F), a novel spectinomycin analog, against gram-positive isolates from cancer patients. Rolston K; Ho DH; Bodey GP Eur J Clin Microbiol Infect Dis; 1989 Mar; 8(3):254-60. PubMed ID: 2523806 [TBL] [Abstract][Full Text] [Related]
8. In vitro susceptibilities of oral pigmented Bacteroides species to trospectomycin and other selected antimicrobial agents. Johnson CC; Wendeler M; Levison ME Antimicrob Agents Chemother; 1990 Aug; 34(8):1597-9. PubMed ID: 2145801 [TBL] [Abstract][Full Text] [Related]
9. The activity in vitro of trospectomycin sulphate (U-63366F) against aminoglycoside-resistant enterococci. Khardori N; Gandhi M; Adame J; Kalvakuntla L; Rosenbaum B; Bodey GP J Antimicrob Chemother; 1990 May; 25(5):777-85. PubMed ID: 2142683 [TBL] [Abstract][Full Text] [Related]
10. Haemophilus test medium interpretive criteria for disk diffusion susceptibility tests with cefdinir, cefetamet, cefmetazole, cefpodoxime, cefdaloxime (RU29246, HR-916 metabolite), and trospectomycin. Jones RN; Erwin ME Diagn Microbiol Infect Dis; 1992; 15(8):693-701. PubMed ID: 1478050 [TBL] [Abstract][Full Text] [Related]
11. Standardization of disk diffusion and agar dilution susceptibility tests for Neisseria gonorrhoeae: interpretive criteria and quality control guidelines for ceftriaxone, penicillin, spectinomycin, and tetracycline. Jones RN; Gavan TL; Thornsberry C; Fuchs PC; Gerlach EH; Knapp JS; Murray P; Washington JA J Clin Microbiol; 1989 Dec; 27(12):2758-66. PubMed ID: 2531756 [TBL] [Abstract][Full Text] [Related]
12. CI-934, a new difluoroquinolone: in vitro antibacterial activity and proposed disk diffusion test interpretive criteria. Fuchs PC; Barry AL; Jones RN; Thornsberry C; Ayers LW; Gavan TL; Gerlach EH Diagn Microbiol Infect Dis; 1987 Mar; 6(3):185-92. PubMed ID: 3471371 [TBL] [Abstract][Full Text] [Related]
13. In vitro susceptibility of Helicobacter pylori to trospectomycin, pirlimycin (U-57930E), mirincamycin (U-24729A) and N-demethyl clindamycin (U-26767A). Westblom TU; Midkiff BR; Czinn SJ Eur J Clin Microbiol Infect Dis; 1993 Jul; 12(7):560-2. PubMed ID: 8404921 [TBL] [Abstract][Full Text] [Related]
14. In-vitro activity of trospectomycin sulphate against Mycoplasma and Ureaplasma species isolated from humans. Yancey RJ; Klein LK J Antimicrob Chemother; 1988 Jun; 21(6):731-6. PubMed ID: 2970452 [TBL] [Abstract][Full Text] [Related]
15. Antibacterial activity of WY-49605 compared with those of six other oral agents and selection of disk content for disk diffusion susceptibility testing. Fuchs PC; Barry AL; Sewell DL Antimicrob Agents Chemother; 1995 Jul; 39(7):1472-9. PubMed ID: 7492088 [TBL] [Abstract][Full Text] [Related]
16. The in vitro activity of trospectomycin against anaerobic bacteria. Chisari G; Lo Bue AM; Nicoletti G J Chemother; 1995 Dec; 7(6):515-8. PubMed ID: 8667035 [TBL] [Abstract][Full Text] [Related]
17. Combined activity of trospectomycin and colloidal bismuth subcitrate against Helicobacter pylori in vitro. Vogt K; Rodloff AC; Hahn H Infection; 1991; 19(3):138-9. PubMed ID: 1832417 [TBL] [Abstract][Full Text] [Related]
18. Trospectomycin, a novel spectinomycin analogue: antibacterial activity and preliminary human pharmacokinetics. Zurenko GE; Ford CW; Novak E Drugs Exp Clin Res; 1988; 14(6):403-9. PubMed ID: 2975212 [TBL] [Abstract][Full Text] [Related]
19. In vitro activities of the spectinomycin analog U-63366 and four quinolone derivatives against Neisseria gonorrhoeae. Peeters M; Van Dyck E; Piot P Antimicrob Agents Chemother; 1984 Oct; 26(4):608-9. PubMed ID: 6240224 [TBL] [Abstract][Full Text] [Related]
20. 3-0-demethyl fortimicin A: in vitro activity and interpretive zone standards for disk diffusion susceptibility tests. Barry AL; Jones RN; Thornsberry C; Gavan TL; Gerlach EH; Sommer HM Eur J Clin Microbiol; 1984 Dec; 3(6):531-7. PubMed ID: 6441709 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]